Finance

Lists
Q1 2027 earnings • released • Revenue beat +4.31%
See results
4547:TYO
Kissei Pharmaceutical Co Ltd
Â¥3,855.00
-5.63%
(-230.00) 1D
Aug 3, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4547...
Open
Â¥3,895
High
Â¥3,910
Low
Â¥3,785
Mkt. cap
179.42B
Avg. vol.
80.66K
Volume
148.50K
Dividend
3.11%
Quarterly dividend
Â¥30
Ex-dividend date
Sep 29, 2026
P/E ratio
11.43
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥337
Shares outstanding
46.72M
No. of employees
2K
Open
Â¥3,895
High
Â¥3,910
Low
Â¥3,785
Mkt. cap
179.42B
Avg. vol.
80.66K
Volume
148.50K
Dividend
3.11%
Quarterly dividend
Â¥30
Ex-dividend date
Sep 29, 2026
P/E ratio
11.43
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥337
Shares outstanding
46.72M
No. of employees
2K
News stories
From sources across the web
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include: Difelikefalin Fostamatinib Linzagolix Mitiglinide Remogliflozin etabonate Silodosin Tranilast In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79K
FoundedAug 9, 1946
HeadquartersMatsumoto, Nagano, Japan
SectorPharmaceutical industry
Websitekissei.co.jp
Last report
Jul 31, 2026
Fiscal period
Q1 2027
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
23.39B / 22.42B
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
23.64B
26.80B
24.77B
23.39B
Cost of goods sold
12.03B
14.50B
13.95B
11.96B
Cost of revenue
12.03B
14.50B
13.95B
11.96B
Research and development expenses
-
-
22.52B
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
20.55B
9.15B
-15.41B
10.34B
Operating expense
20.55B
9.15B
10.07B
10.34B
Total operating expenses
32.59B
23.65B
24.02B
22.29B
Operating income
-8.95B
3.16B
756.00M
1.10B
Other non operating income
1.00M
10.00M
-10.00M
10.00M
EBT including unusual items
3.66B
4.20B
3.28B
6.29B
EBT excluding unusual items
-8.82B
3.52B
948.00M
1.82B
Income tax expense
305.00M
915.00M
482.00M
1.53B
Effective tax rate
8.33%
21.81%
14.68%
24.32%
Other operating expenses
-
-
129.00M
-
Net income
3.26B
3.23B
2.76B
4.72B
Net profit margin
13.81%
12.05%
11.16%
20.19%
Earnings per share
-
-
-
-
Interest and investment income
212.00M
614.00M
224.00M
729.00M
Interest expense
-7.00M
-7.00M
-8.00M
-8.00M
Net interest expenses
205.00M
607.00M
216.00M
721.00M
Depreciation and amortization charges
-
-
2.83B
-
EBITDA
-7.82B
4.31B
1.92B
2.26B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps